Eli Lilly Cancer Drug Developed in China Gets FDA Rejection
For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter. It's completely free and we guarantee you'll learn something new every day.
The FDA sent Eli Lilly back to the drawing board Thursday, but it might not be worth the hassle.
Regulators rejected a lung cancer drug the pharmaceutical giant developed with a Chinese partner, urging them to conduct further trials. But analysts say the cost may be too steep to continue, potentially setting a worrisome precedent for the growing number of US firms looking to import drugs developed in the world's most populous country.
Source Fool.com
